Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of some unusual options trading activity on Wednesday. Stock traders bought 50,051 call options on the stock. This is an increase of approximately 298% compared to the typical daily volume of 12,577 call options.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Morgan Stanley increased their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a report on Thursday, May 14th. Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Finally, Bank of America lowered their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX traded up $0.22 during midday trading on Wednesday, reaching $3.19. 16,224,865 shares of the stock were exchanged, compared to its average volume of 16,596,818. Recursion Pharmaceuticals has a twelve month low of $2.77 and a twelve month high of $7.18. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.47 and a quick ratio of 5.47. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of -2.64 and a beta of 1.05. The business’s 50-day moving average price is $3.27 and its 200 day moving average price is $3.87.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The business’s revenue was down 56.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.50) EPS. On average, sell-side analysts expect that Recursion Pharmaceuticals will post -1.02 EPS for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $3.52, for a total value of $105,600.00. Following the transaction, the director owned 6,199,863 shares of the company’s stock, valued at $21,823,517.76. This represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $3.39, for a total transaction of $26,970.84. Following the transaction, the chief financial officer directly owned 1,180,318 shares of the company’s stock, valued at approximately $4,001,278.02. This trade represents a 0.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 96,254 shares of company stock worth $320,369. Insiders own 8.43% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. International Assets Investment Management LLC purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $31,000. Integral Investment Advisors Inc. purchased a new position in shares of Recursion Pharmaceuticals during the first quarter worth about $39,000. Sequoia Financial Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter worth about $41,000. MQS Management LLC acquired a new position in Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, Allworth Financial LP raised its stake in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.